Arcus Biosciences, Inc.

RCUS · NYSE
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$283,000-$307,000-$267,000$52,830
Dep. & Amort.$10,000$8,000$14,000$3,843
Deferred Tax$0$0$0$4,772
Stock-Based Comp.$76,000$73,000$0$55,000
Change in WC$22,000-$71,000$623,000-$375,618
Other Non-Cash$5,000-$9,000$68,000$3,474
Operating Cash Flow-$170,000-$306,000$438,000-$256,171
Investing Activities
PP&E Inv.-$6,000-$24,000-$6,000-$26,078
Net Acquisitions$0$0$0-$22,000
Inv. Purchases-$1,043,000-$788,000-$1,241,000-$718,865
Inv. Sales/Matur.$965,000$1,006,000$837,000$741,075
Other Inv. Act.$0$0-$3,000$22,000
Investing Cash Flow-$84,000$194,000-$413,000-$3,868
Financing Activities
Debt Repay.$47,000$0$10,000$5,000
Stock Issued$228,000$25,000$23,000$220,000
Stock Repurch.$0$0$0-$6
Dividends Paid$0$0$0$0
Other Fin. Act.$2,000$8,000$0$12,340
Financing Cash Flow$277,000$33,000$33,000$237,340
Forex Effect$0$0$86$0
Net Chg. in Cash$23,000-$79,000$58,086-$22,699
Supplemental Information
Beg. Cash$130,000$209,000$147,914$173,618
End Cash$153,000$130,000$206,000$150,919
Free Cash Flow-$176,000-$330,000$432,000-$282,249
Arcus Biosciences, Inc. (RCUS) Financial Statements & Key Stats | AlphaPilot